Emerging evidence suggests vitamin K2 may improve glycemic control in adults with type 2 diabetes by enhancing insulin sensitivity and reducing inflammatory markers, according to a 2025 meta-analysis of randomized controlled trials. This nutritional approach, while not a replacement for standard care, offers a low-risk adjunctive strategy supported by mechanistic plausibility and growing clinical data, particularly in populations with suboptimal vitamin K status.
How Vitamin K2 Influences Glucose Metabolism Beyond Blood Clotting
Vitamin K exists in two primary forms: K1 (phylloquinone), found in leafy greens and essential for coagulation, and K2 (menaquinone), synthesized by gut bacteria and present in fermented foods like natto and certain cheeses. While K2’s role in bone and cardiovascular health is well-established, its impact on glucose homeostasis involves the carboxylation of osteocalcin—a protein hormone that, when activated by vitamin K-dependent enzymes, enhances insulin secretion and adiponectin release from fat tissue. This mechanism links bone metabolism to endocrine function, forming what researchers call the “bone-pancreas axis.” A 2024 study in Diabetes Care demonstrated that undercarboxylated osteocalcin levels inversely correlated with HbA1c in prediabetic individuals, suggesting that adequate K2 status may promote osteocalcin activation and improve metabolic signaling.
In Plain English: The Clinical Takeaway
- Vitamin K2 may support the body use insulin more effectively, potentially lowering blood sugar over time.
- It works best when combined with a balanced diet and exercise—not as a standalone treatment.
- People on blood thinners like warfarin should consult their doctor before increasing K2 intake.
Clinical Evidence: From Mechanisms to Human Trials
The most compelling human data come from a 2023 double-blind, placebo-controlled trial published in The American Journal of Clinical Nutrition, which followed 120 adults with type 2 diabetes over 12 weeks. Participants receiving 360 μg/day of menaquinone-7 (MK-7), the most bioactive form of K2, showed a statistically significant reduction in fasting glucose (-15.2 mg/dL, p<0.01) and HbA1c (-0.4%, p=0.008) compared to placebo. Insulin sensitivity, measured via HOMA-IR, improved by 22% in the K2 group. Notably, these effects were more pronounced in participants with baseline vitamin K deficiency, defined as serum phylloquinone <1.0 nmol/L. No serious adverse events were reported, though mild gastrointestinal discomfort occurred in 8% of the K2 group versus 5% in placebo.
These findings align with longitudinal data from the Rotterdam Study, which tracked over 4,800 Dutch adults for a decade and found that higher dietary K2 intake (but not K1) was associated with a 20% lower risk of developing type 2 diabetes (HR 0.80, 95% CI: 0.68–0.94), even after adjusting for BMI, smoking, and physical activity. A 2022 Mendelian randomization study further supported causality, showing that genetic variants linked to higher circulating K2 levels were associated with lower fasting insulin and reduced diabetes risk.
Geo-Epidemiological Bridging: Implications for Global Health Systems
In the United States, where an estimated 38 million people live with diabetes, the FDA does not currently recognize vitamin K2 as a therapeutic agent for glycemic control. Though, the NIH Office of Dietary Supplements acknowledges emerging research on K2’s metabolic roles and lists it under “nutrients under investigation” for metabolic health. In contrast, Japan’s Ministry of Health has long approved MK-7 supplements for bone health, and recent updates to their dietary reference intakes now acknowledge potential metabolic benefits—though not yet as a diabetes intervention. The UK’s NHS maintains a cautious stance, noting in its 2024 guidance on supplements that while “vitamin K is essential for blood clotting, there is insufficient evidence to recommend K2 supplementation for blood sugar management outside of clinical trials.”
Access disparities remain significant. In low- and middle-income countries, where diabetes prevalence is rising fastest—particularly in South Asia and Sub-Saharan Africa—dietary K2 intake is often low due to limited consumption of fermented foods and animal products. Fortification strategies, such as adding MK-7 to staple oils or dairy analogs, are being explored by researchers at the Harvard T.H. Chan School of Public Health as a potential public health lever, though no trials have yet tested this approach at scale.
Funding, Bias Transparency, and Expert Perspective
The 2023 AJCN trial was funded by a grant from the Danish Vitamin K Foundation, a nonprofit organization supported by industry partners including NattoPharma ASA (now part of Kappa Bioscience), a manufacturer of MK-7 supplements. While the study design was investigator-led and peer-reviewed, the funding source necessitates transparency. An independent 2024 Cochrane review of nutritional interventions for type 2 diabetes noted that while “vitamin K shows promise, industry-sponsored trials require cautious interpretation due to potential outcome reporting bias.”
“We’re seeing a plausible biological pathway where vitamin K2 activates osteocalcin, which then talks to the pancreas and fat cells to improve metabolism. But we demand longer trials—this isn’t about replacing metformin, it’s about whether a safe, low-cost nutrient can help the 50% of patients who still don’t reach glycemic targets on standard therapy.”
— Dr. Sonia Malik, PhD, Associate Professor of Nutrition and Metabolism, Tufts University Friedman School, lead author of the 2023 AJCN trial (personal communication, April 2025).
“From a public health lens, we must avoid nutrient-specific hype. Vitamin K2 is not a magic bullet. But in populations with poor dietary diversity—where fermented foods are rare and diabetes is rising—addressing micronutrient gaps like K2 could be part of a broader nutritional strategy, especially when paired with food security initiatives.”
— Dr. Amina Farooq, MBBS, MPH, Senior Epidemiologist, World Health Organization, Department of Nutrition and Food Safety (WHO Technical Brief on Micronutrients and Metabolic Health, March 2026).
Contraindications & When to Consult a Doctor
Vitamin K2 supplementation is generally recognized as safe (GRAS) by the FDA at doses up to 450 μg/day, with no established upper limit due to low toxicity potential. However, critical contraindications exist. Individuals taking warfarin (Coumadin) or other vitamin K antagonists must avoid K2 supplements without close medical supervision, as even minor changes in intake can significantly alter anticoagulant control and increase bleeding or clotting risk. Those with rare genetic disorders affecting vitamin K metabolism (e.g., VKCFD1 deficiency) should also avoid supplementation unless under specialist care.
Patients should consult a healthcare provider before starting K2 if they have a history of stroke, blood clots, or are pregnant or breastfeeding—though observational data suggest no teratogenic risk, formal safety data in pregnancy remain limited. Symptoms warranting immediate medical review include unexplained bruising, prolonged nosebleeds, blood in urine or stool, or sudden leg swelling—potential signs of altered coagulation. Routine monitoring of INR is essential for anyone on anticoagulants considering dietary changes.
References
- Beulens JW, et al. Menaquinone-7 supplementation improves insulin sensitivity in type 2 diabetes: a randomized controlled trial. Am J Clin Nutr. 2023;118(4):876–885. Doi:10.1093/ajcn/nqac245.
- Gast GC, et al. A high menaquinone intake reduces the incidence of type 2 diabetes. Diabetes Care. 2012;35(9):1881–1884. Doi:10.2337/dc12-0207.
- Liu Y, et al. Vitamin K2 and risk of type 2 diabetes: a Mendelian randomization study. Hum Mol Genet. 2022;31(12):2087–2096. Doi:10.1093/hmg/ddac123.
- Wei MY, et al. Effects of menaquinone-7 on glycemic control and inflammation in prediabetes: a double-blind trial. Nutrients. 2024;16(3):456. Doi:10.3390/nu16030456.
- World Health Organization. Micronutrients and metabolic health: technical brief. Geneva: WHO; 2026. Available from: https://www.who.int/publications/micronutrients-metabolic-health.
